PAVmed faces an existential crisis characterized by a near-total erosion of its commercial footprint and an unsustainable cost structure that consistently outpaces revenue generation. The company's reliance on non-operating accounting adjustments to mask core ...
Price trend, volume and key moving averages
Trailing total returns as of 10/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 14, 2026 | -$0.87-85.1% vs -$0.47 | $33,000-31.3% vs $48,000 |
Q2 2026 May 15, 2026 | -$4.42-540.6% vs -$0.69 | $22,000-70.3% vs $74,000 |
Q2 2026 Mar 30, 2026 | -$1.05-50.0% vs -$0.70 | — vs $74,000 |
Q2 2026 Mar 26, 2026 | -$2.05+54.4% vs -$4.50 | $52,000+108.0% vs $25,000 |
PAVmed (NASDAQ: PAVM - Get Free Report) and InMode (NASDAQ: INMD - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, profitability, risk and earnings. Valuation and Earnings This table compares PAVmed and InMode"s
Medicare Advisory Panel recommends maintaining EsoGuard's original gapfill payment basis under the Clinical Laboratory Fee Schedule AMA CPT Editorial Panel approves a new Category III CPT code for non-endoscopic cell collection procedures performed with EsoCheck Proposal for a new ICD-10-CM diagnosis code identifying positive EsoGuard results draws a favorable response from the CDC/NCHS ICD-10 Coordination and Maintenance Committee NEW YORK, Sept. 22, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced advances in multiple payment, billing, and coding pathways for its EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device, following three public meetings held last week.
PAVmed Inc. (PAVM) Q2 2026 Earnings Call Transcript
Veris Health accelerated its commercial engagement with OSU-The James Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ® Conference call and webcast to be held today, August 14, at 8:30 AM EDT NEW YORK, Aug. 14, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid"), Veris Health Inc. ("Veris"), and Octeris Medical Inc. ("Octeris"), and reported financial results for the second quarter ended June 30, 2026. Conference Call and Webcast The webcast will take place on Friday, August 14, 2026, at 8:30 AM and is accessible in the investor relations section of the Company's website at pavmed.com.
Benchmark PAVM against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for PAVmed Inc. (PAVM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.17 | $13.6M | -0.39 | -97.63% | 564.79% | 5.25% | — | |
| $14.68 | $1.7B | -12.03 | 8.28% | -21.25% | -44% | — | |
| $20.66 | $1.52B | 6.26 | 18.52% | 80.56% | 30.03% | — | |
| $0.23 | $3.93M | -0.11 | -25.96% | -4791.48% | -106.13% | — | |
| $11.11 | $1.71B | -11.57 | 24.95% | -13.5% | -818.99% | — | |
| $178.88 | $10.55B | -54.54 | 32.33% | -30.68% | -27.07% | — |
PAVmed Inc. (PAVM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
PAVmed Inc. (PAVM) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 14, 2026·SEC
Jun 24, 2026·SEC
May 15, 2026·SEC
Get notified when PAVM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PAVmed Inc. (PAVM) stock FAQ — growth, dividends, profitability & financials explained
PAVmed Inc. (PAVM) reported $0.1M in revenue for fiscal year 2025.
PAVmed Inc. (PAVM) saw revenue decline by 97.6% over the past year.
PAVmed Inc. (PAVM) reported a net loss of $12.1M for fiscal year 2025.
PAVmed Inc. (PAVM) has a return on equity (ROE) of 5.3%. This is below average, suggesting room for improvement.
PAVmed Inc. (PAVM) had negative free cash flow of $2.63B in fiscal year 2025, likely due to heavy capital investments.
